TRexBio secured an additional $50 million in a Series B extension to advance TRB‑061 and other Treg‑focused programs toward human testing. The financing will support Phase 1 work in atopic dermatitis and early testing in ulcerative colitis and other immune conditions. TRB‑061 targets tumor necrosis factor receptor 2 (TNFR2) to activate regulatory T cells (Tregs) and modulate inflammation without broad immunosuppression, TRexBio said. The round included participation from Janus Henderson, Alexandria Venture Investments and Eli Lilly among others. The raise arrives as multiple companies pursue next‑generation immunomodulators for eczema and autoimmune disease, intensifying competition while validating interest from strategic and biotech investors in precision Treg approaches.